the aid library

LIST OPTIONS

Filter

5690

Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories

Globan Burden of Disease 2020 Health Financing Collaborator Network The Lancet (2021) CC

The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was di... more

Download (140)

View PDF (145)

From Double Shock to Double Recovery – Implications and Options for Health Financing in the Time of COVID-19

Kurowski, C.; D. B. Evans; A. Tandon et al. The World Bank (2021) CC

The COVID-19 pandemic has resulted in a double shock - health and economic. As of March 1, 2021, COVID-19 has cost more than 2.5 million lives and triggered an economic recession surpassing any economic downturn since World War II. Part I of this paper explores the impact of this current macro-fisc... more

Download (162)

View PDF (179)

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

From emergency response to long-term COVID-19 disease management - Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the r

World Health Organization WHO (2023) C_WHO

The key actions, activities, and approaches in this document are organized within each of the 5Cs (see Table 1 in the PDF) and those of the Strategic preparedness and response plan (SPRP) pillars as follows: National action plan key activities, prioritized for the current context and the current ... more

Download (286)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Conditions for health system resilience in the response to the COVID-19 pandemic in Mauritania

Accoe K.; Kriel B.; Ag Ahmed M. et al. BMJ Global Health (2023) CC

A country’s ability to manage a crisis depends on its level of resilience. Efforts are made to clarify the concept of health system resilience, but its operationalisation remains little studied. In the present research, we described the capacity of the local healthcare system in the Islamic Republ... more

External Link

Global investments in pandemic preparedness and COVID-19: development assistance and domestic spending on health between 1990 and 2026

Global Burden of Disease 2021 Health Financing Collaborator Network The Lancet Glob Health (2023) C2

The COVID-19 pandemic highlighted gaps in health surveillance systems, disease prevention, and treatment globally. Among the many factors that might have led to these gaps is the issue of the financing of national health systems, especially in low-income and middle-income countries (LMICs), as well ... more

The impact of COVID-19 o development assistance

Brown S. Sage Journals (2021) CC

This article analyzes the impact of the COVID-19 pandemic on foreign aid. Using examples from Canadian foreign aid, it argues that, despite the terrible toll it is exacting, the crisis has accelerated some significant positive pre-existing trends, both by destabilizing the perception of aid as flowi... more

External Link

External Link (132)

The impact of COVID-19 on development assistance

Brown S. Sage Journals (2021) CC

This article analyzes the impact of the COVID-19 pandemic on foreign aid.

Questions and Answers on Covid-19 and Diabetes

World Health Organization WHO African Region (2020) C_WHO

Does Diabetes make someone vulnerable to getting COVID-19: People with Diabetes are not more likely to get the virus compared to the general public. However, if they contact CoVID-19, people with diabetes are more likely to have serious complications and become seriously ill from COVID-19, than t... more

Fact-sheet: If I have Diabetes, what do I need to know about COVID-19? Q and A on Covid-19 and NCDS

Pan American Health Organization PAHO; World Health Organization WHO (2020) C_WHO

ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19? People with diabetes are more likely to become seriously ill from COVID-19, than those who do not have diabetes. Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.

Si tengo diabetes, ¿qué debo saber acerca de la COVID-19? 21 de mayo del 2020

Pan American Health Organization PAHO; World Health Organization WHO (2020) C_WHO

ARE PEOPLE WITH DIABETES MORE LIKELY TO GET COVID-19? • People with diabetes are more likely to become seriously ill from COVID-19, than those who do not have diabetes. • Unfortunately, persons with diabetes who get COVID-19 are more likely to die than those without diabetes.

Se tenho diabetes, o que preciso saber sobre a COVID-19?

Pan American Health Organization PAHO; World Health Organization WHO (2020) C_WHO

Nigeria: a primary health care case study in the context of the COVID-19 pandemic

World Health Organisation (WHO) (2024) CC

In 2018 the Astana Declaration reaffirmed a global commitment to PHC as a cornerstone of sustainable health systems for accelerated progress on universal health coverage (UHC) (1). The vision for PHC in the 21st century is for a wholeof-government and whole-of-society approach to health that combine... more

Action Plan for Implementation of Recommendations from the Evaluation of PAHO's Response to COVID-19

Pan American Health Organisation PAHO (2024) CC

An external team evaluated PAHO’s response to COVID-19 to provide an independent assessment of the Pan American Sanitary Bureau’s (PASB) performance regarding preparedness for and response to the COVID-19 pandemic. The evaluations’ final report culminates with eight recommendations for actions... more

Sharing successful strategies from the Eastern Mediterranean Region in mitigating noncommunicable diseases and mentalhealth disorders during the COVID-19pandemic and beyond

World Health Organization (WHO) Regional Office for the Eastern Mediterranean World Health Organization (WHO) Regional Office for the Eastern Mediterranean (2023) C_WHO

The "Stories from the field" document by the WHO Regional Office for the Eastern Mediterranean shares effective strategies from the Eastern Mediterranean Region for addressing noncommunicable diseases (NCDs) and mental health challenges, particularly during the COVID-19 pandemic. It highlights regio... more

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors 2023

World Health Organization WHO (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more

Webinar Series: Tackling NCDs during the time of COVID-19

Pan American Health Organization PAHO; World Health Organization WHO (2021) C_WHO

"Tackling Noncommunicable Diseases (NCDs), risk factors and mental health during the time of COVID-19" is a series of high-level strategic discussions on transforming the approach to noncommunicable diseases, its risk factors and mental health as a result of the pandemic in terms of strengthening he... more

Publication: Gendered Impacts of the COVID-19 Crisis in Uganda and Opportunities for an Inclusive and Sustainable Recovery

Alys, W.; Aziz, A.; Caran Ann, M. (2022) CC2

As Uganda builds back from the COVID-19 shock, the Ugandan government is strengthening its commitment to a more gender-inclusive and sustainable economy. This report supports these efforts by describing the gendered impacts of COVID-19 and provides recommendations for Ugandan policy makers and World... more

UNICEF’s HIV Programming in the Context of COVID-19: Building back better for children, adolescents and women

Unicef (2021) CC2

The coronavirus outbreak that began in 2019 (COVID-19) threatens to reverse years of hard-won gains in preventing and treating HIV. Fragile health systems are further stressed as health workers navigate an increased client load and demands at work while also being concerned for their own health and ... more